Source: Pharmacy Times articles
An expert discusses the promising results of elranatamab as a consolidative therapy for relapsed/refractory multiple myeloma, enhancing patient outcomes.
Recent Content
- Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
- (no title)
- (no title)
- Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
- 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
- Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance
- Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies
- (no title)
- FDA OK’s belantamab mafodotin-blmf for multiple myeloma
- Using RNA-seq for detecting MRD in multiple myeloma: high sensitivity and prognostic value